| Q33621078 | A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge |
| Q38067243 | Animal models for neonatal diseases in humans |
| Q45254399 | Comparison of the efficacy of rotavirus VLP vaccines to a live homologous rotavirus vaccine in a pig model of rotavirus disease |
| Q35275131 | Cross-linking of rotavirus outer capsid protein VP7 by antibodies or disulfides inhibits viral entry |
| Q36175693 | Differential profiles and inhibitory effect on rotavirus vaccines of nonantibody components in breast milk from mothers in developing and developed countries |
| Q36175711 | Dose sparing and enhanced immunogenicity of inactivated rotavirus vaccine administered by skin vaccination using a microneedle patch |
| Q54445723 | Evaluation of recombinant BCG expressing rotavirus VP6 as an anti-rotavirus vaccine. |
| Q39873188 | Expression and characterization of human group C rotavirus virus-like particles in insect cells. |
| Q34332253 | Expression and self-assembly of norwalk virus capsid protein from venezuelan equine encephalitis virus replicons |
| Q55405177 | Gamma-irradiated rotavirus: A possible whole virus inactivated vaccine. |
| Q34108591 | Global impact of rotavirus vaccines |
| Q33813867 | Heterotypic protection and induction of a broad heterotypic neutralization response by rotavirus-like particles |
| Q45253311 | Immunity to homologous rotavirus infection in adult mice. |
| Q40676887 | Immunogenicity and protective efficacy of a formalin-inactivated rotavirus vaccine combined with lipid adjuvants |
| Q44572737 | Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice |
| Q42233820 | Immunogenicity and protective efficacy of yeast extracts containing rotavirus-like particles: a potential veterinary vaccine. |
| Q44773885 | Immunogenicity and virus-like particle formation of rotavirus capsid proteins produced in transgenic plants |
| Q47554106 | Inactivated rotavirus vaccine by parenteral administration induces mucosal immunity in mice. |
| Q84431082 | Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets |
| Q37308484 | Inactivated rotavirus vaccines: a priority for accelerated vaccine development |
| Q40564864 | Incidence and risk factors of paediatric rotavirus diarrhoea in northern Ghana |
| Q36992562 | Inhibitory effect of breast milk on infectivity of live oral rotavirus vaccines |
| Q34213447 | Intestinal epithelia activate anti-viral signaling via intracellular sensing of rotavirus structural components |
| Q33914464 | Norwalk virus vaccines: challenges and progress |
| Q36903971 | Oral rotavirus vaccines: how well will they work where they are needed most? |
| Q81548527 | Parenteral administration of RF 8-2/6/7 rotavirus-like particles in a one-dose regimen induce protective immunity in mice |
| Q44126179 | Protection against rotavirus shedding after intranasal immunization of mice with a chimeric VP6 protein does not require intestinal IgA. |
| Q45748767 | Recombinant Norwalk virus-like particles given orally to volunteers: phase I study |
| Q45669616 | Recombinant virus-like particles of a norovirus (genogroup II strain) administered intranasally and orally with mucosal adjuvants LT and LT(R192G) in BALB/c mice induce specific humoral and cellular Th1/Th2-like immune responses |
| Q33849144 | Rotavirus 2/6 virus-like particles administered intranasally in mice, with or without the mucosal adjuvants cholera toxin and Escherichia coli heat-labile toxin, induce a Th1/Th2-like immune response |
| Q34550164 | Rotavirus vaccines: current prospects and future challenges |
| Q58754584 | Rotavirus-like particle production: Simulation of protein production and particle assembly |
| Q48303627 | Sequence analysis of the VP4, VP6, VP7, and NSP4 gene products of the bovine rotavirus WC3. |
| Q36185718 | Skin Vaccination against Rotavirus Using Microneedles: Proof of Concept in Gnotobiotic Piglets |
| Q34357038 | Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles |
| Q38172132 | The gastrointestinal frontier: IgA and viruses |
| Q59206999 | The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant |
| Q34618449 | The role of serum antibodies in the protection against rotavirus disease: an overview |
| Q62128249 | Virus-like particle-based vaccines for animal viral infections |
| Q37666808 | Virus-like particles as a vaccine delivery system: myths and facts |
| Q35295832 | Virus-like particles as immunogens |
| Q38019283 | Virus-like particles: the new frontier of vaccines for animal viral infections. |